Tovaxin is a novel anti-T-cell therapeutic vaccine that parallels the concept of autologous cancer vaccines. Instea of modifying cancerous cells, TovaxinTM consists of attenuated autoreactive T cells. Tovaxin is being developed by Opexa Therapeutics in Houston, Texas